Ge Long Hui A P P·2026-01-23 07:58Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) has received approval from the National Medical Products Administration for the production of Maleate Avatrombopag Tablets, which are indicated for adult patients with chronic liver disease-related thrombocytopenia and chronic primary immune thrombocytopenia (ITP) [1] Group 1: Product Approval - The Maleate Avatrombopag Tablets are approved for use in adult patients undergoing elective diagnostic procedures or surgeries related to chronic liver disease [1] - The product is also suitable for adult patients with chronic primary immune thrombocytopenia who have previously shown poor response to treatments such as corticosteroids and immunoglobulins [1] - The drug was originally developed by AkaRx Inc. in the United States and was launched in the U.S. market in 2018 [1] Group 2: Development and Investment - Shanghai Pharmaceuticals submitted the registration application for the drug to the National Medical Products Administration in August 2024, which has been accepted [1] - As of the date of the announcement, the company has invested approximately RMB 9.8961 million in the research and development of this product [1] Group 3: Market Competition - The main domestic manufacturers of this drug in China include Fosun Pharma (Jiangsu) Pharmaceutical Group Co., Ltd., Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd., and Qilu Pharmaceutical Co., Ltd. [1]